Radiotherapy for Ewing sarcoma: A 5 year experience from Iran cancer institute

Abstract

Background: Ewing Sarcoma Family of Tumors (ESFTs) is the second most common primary tumors of bone in childhood. The decision regarding the op mal modality for achieving local tumor control remains uncertain. The aim of this study was to report the clinical features and outcome as well as reviewing risk factors in pa ents. Materials and Methods: This retrospec ve study included 75 ESFTs pa ents who were treated at cancer ins tute between 2004 and 2009. Files of all pa ents with ESFTs were reviewed retrospec vely and we called them for follow up. Specific data were collected with regard to the age at diagnosis, gender, tumor site and size, clinical stage, surgical procedure, plan of radiotherapy and treatment outcome (5-year and median survival). Results: The mean age at diagnosis was 21 that ranged from 1 to 52 years (SD = 9.6). The mean tumor size at diagnosis was 4.8±4.48 cm. The percent of biopsy only, par al and complete resec on was 54.7% (41 pa ents), 6.7% (5 pa ents) and 37.3% (28 pa ents) respec vely. Radiotherapy was done as defini ve treatment or postopera vely (adjuvant) in 46 (61.3%) and 16 (21.4%) pa ents respec vely. Overall 5 year survival was 24% and median survival for pa ents with and without metastases was 21±17 and 75±10 months. Conclusion: Presence of metastases, age at diagnosis, posi ve surgical margin and tumor size were the prognos c factors that influenced outcome of pa ents. This study suggests that radia on therapy is an acceptable local treatment modality in pa ents with Ewing sarcoma family.Keywords: Ew ing sarcom a, radiotherapy, m ultim odality treatm ent.

Pediatrik Ewing Sarkoma Hastalarının Multimodal Tedavisinde Adjuvan Radyoterapi

“…The median age of the patients at the time of diagnosis DOI: 10.37990/medr.1093314 was 10.5 (range [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. The age of the patients was divided into two groups as under ten years old and above (7); 6 (%40) patients were younger than ten years, and 9 (60%) patients were ten years or older.…”

“…No randomized trial evaluates the role of radiotherapy in the curative or adjuvant setting. Most of the data in the literature consist of radiotherapy results obtained from retrospective analyses (Table 1) (7,(13)(14)(15)(16)(17)(18)(19). Although different chemotherapy schemes and different patient groups were evaluated in these studies, generally, local control and survival rates were reported to be higher in patients who received radiotherapy as a part of multimodal therapy.…”